Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 634-635 |
| Number of pages | 2 |
| Journal | Osteoporosis International |
| Volume | 17 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Apr 2006 |
| Externally published | Yes |
Fingerprint
Cite this
}
Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]. / Naunton, M.; Duyvendak, M.; Peterson, G. M.; Brouwers, J. R B J.
In: Osteoporosis International, Vol. 17, No. 4, 01.04.2006, p. 634-635.Research output: Contribution to journal › Letter
TY - JOUR
T1 - Practice patterns in osteoporosis prevention in patients on glucocorticoids [1]
AU - Naunton, M.
AU - Duyvendak, M.
AU - Peterson, G. M.
AU - Brouwers, J. R B J
PY - 2006/4/1
Y1 - 2006/4/1
N2 - We have read the recent results from the study on osteoporosis prevention in chronic (>90 days) glucocorticoid users by Feldstein et al. [1] and have three comments. 1. We believe that any apparent under-treatment may be partly due to the fact that the data analysed were collected from January 2000–December 2001. The American College of Rheumatology (ACR) guidelines for prevention of glucocorticoid-induced osteoporosis were published in July 2001 and recommended that osteoporosis prevention should be considered in those patients treated on ≥5 mg of prednisolone per day [3]. The guidelines available before this suggested that patients should be considered for osteoporosis prevention if the dose was greater than 7.5 mg per day, and the patients were treated for >6 months with the glucocorticoid [4]. We believe to be fair to the prescribers and other primary-care clinicians it should be noted that at the time that these data were collected most would only be aware that patients treated with ≥7.5 mg prednisolone should be considered for osteoporosis prevention.
AB - We have read the recent results from the study on osteoporosis prevention in chronic (>90 days) glucocorticoid users by Feldstein et al. [1] and have three comments. 1. We believe that any apparent under-treatment may be partly due to the fact that the data analysed were collected from January 2000–December 2001. The American College of Rheumatology (ACR) guidelines for prevention of glucocorticoid-induced osteoporosis were published in July 2001 and recommended that osteoporosis prevention should be considered in those patients treated on ≥5 mg of prednisolone per day [3]. The guidelines available before this suggested that patients should be considered for osteoporosis prevention if the dose was greater than 7.5 mg per day, and the patients were treated for >6 months with the glucocorticoid [4]. We believe to be fair to the prescribers and other primary-care clinicians it should be noted that at the time that these data were collected most would only be aware that patients treated with ≥7.5 mg prednisolone should be considered for osteoporosis prevention.
UR - http://www.scopus.com/inward/record.url?scp=33645211707&partnerID=8YFLogxK
U2 - 10.1007/s00198-005-0055-0
DO - 10.1007/s00198-005-0055-0
M3 - Letter
VL - 17
SP - 634
EP - 635
JO - Osteoporosis International
JF - Osteoporosis International
SN - 0937-941X
IS - 4
ER -